FREE BENEFIT (our ‘thank you’) for participating Professional Investors

Cancer immunotherapy with personalized precision (n=1) neoantigen targeting is an important new tool for oncologists to treat patients, usually in combination with surgery, radiation and chemotherapy. Artificial Intelligence (AI) is a transformative new technology for neoantigen discovery. Normax requires Professional Investment to deliver a scalable business model for hospitals and clinics for local delivery of personalized precision (n=1) mRNA cancer immunotherapies for people living with cancer in the US, UK and EU, in cooperation with leading hospitals and oncologists and strategic industrial partners.

The NRMX Free Benefit (our ‘thank you’) is a legally binding, pro bono, non-fungible opportunity for participating Professional Investors to benefit from the novel Normax Educated Antigen Receptor Therapy (EARTh) GMP Process for Personalized precision (n=1) mRNA Vaccines for Cancer Patients. The NRMX Free Benefit may be gifted by Professional Investors to any person, or any charity, but may never be sold. Patients Participating in EARTh Clinical Trial Phase-I will be treated at leading participating hospitals in United Kingdom, Belgium, Luxembourg, Switzerland and California. The NRMX Free Benefit is our way of saying “thank you” to our participating Professional Investors.